University of Utah, Department of Internal Medicine, 295 Chipeta Way, Salt Lake City, UT 84132, USA.
University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience, 260 Stetson Street, Cincinnati, OH 45267-0559, USA; Center for Addiction Research, University of Cincinnati College of Medicine, 3230 Eden Ave, Cincinnati, OH 45267, USA.
Drug Alcohol Depend. 2022 May 1;234:109406. doi: 10.1016/j.drugalcdep.2022.109406. Epub 2022 Mar 16.
Included among the significant risk factors for opioid overdose is concomitant use of other central nervous system depressants, particularly alcohol. Given the continued expansion of community pharmacy in the continuum of care, it is imperative to characterize alcohol use among pharmacy patients dispensed opioids in order to establish a foundation for identification and intervention in these settings.
This secondary analysis utilized data from a one-time, cross-sectional health assessment conducted among patients dispensed opioid medications in 19 community pharmacies in Indiana and Ohio. Adult, English speaking, patients not receiving cancer care who were dispensed opioid medications were asked to self-report alcohol and substance use, behavioral and physical health, and demographic information. Descriptive and logistic regression analyses were employed to characterize alcohol use/risky alcohol use and patient characteristics associated therewith.
The analytical sample included 1494 individuals. Participants were on average 49 years of age (Standard Deviation=14.9)-with 6% being persons of color (n = 89). Weekly drinking was reported by 18.1% (n = 204) and daily drinking was reported by 6.8% (n = 77) of the study sample, with a total of 143 (9.6%) participants reporting moderate/high risk drinking. Males (Adjusted Odds Ratio [AOR]=1.94, 95% CI=1.3,2.9), those with higher pain interference (AOR=1.44, 95% CI=1.0,2.0), overdose history (AOR=1.93, 95% CI=1.1,3.5), sedative use (AOR=2.11, 95% CI=1.3,3.5), and tobacco use (AOR=2.41, 95% CI=1.6,3.7) had increased likelihood of moderate/high risk alcohol use (all p < 0.05).
Medication labeling and clinical guidelines clearly indicate that patients should abstain from concomitant use of opioids and alcohol. This study has identified rates and associated risk factors of risky alcohol use among a clinical sample of community pharmacy patients dispensed opioid medications. Continuing this line of research and potential clinical service development has the ability to improve patient safety through addressing a significant gap within the current opioid epidemic.
阿片类药物过量的重要危险因素之一是同时使用其他中枢神经系统抑制剂,特别是酒精。鉴于社区药房在连续护理中的持续扩展,必须确定在这些环境中配给阿片类药物的药房患者的酒精使用情况,以便为识别和干预建立基础。
本二次分析利用了在印第安纳州和俄亥俄州的 19 家社区药房配给阿片类药物的患者进行的一次性横断面健康评估的数据。接受癌症治疗的成年、讲英语的患者在配给阿片类药物时被要求自我报告酒精和物质使用、行为和身体健康以及人口统计学信息。采用描述性和逻辑回归分析来描述与酒精使用/风险酒精使用相关的特征和患者特征。
分析样本包括 1494 人。参与者的平均年龄为 49 岁(标准差=14.9)-其中 6%为有色人种(n=89)。18.1%(n=204)的人报告每周饮酒,6.8%(n=77)的人报告每天饮酒,共有 143 人(9.6%)报告中度/高度风险饮酒。男性(调整后的优势比[OR]=1.94,95%CI=1.3,2.9)、疼痛干扰程度较高(OR=1.44,95%CI=1.0,2.0)、有过量史(OR=1.93,95%CI=1.1,3.5)、使用镇静剂(OR=2.11,95%CI=1.3,3.5)和吸烟(OR=2.41,95%CI=1.6,3.7)的患者更有可能出现中度/高度风险的酒精使用(均 p<0.05)。
药物标签和临床指南明确指出,患者应避免同时使用阿片类药物和酒精。本研究确定了社区药房配给阿片类药物的临床患者样本中风险酒精使用的发生率和相关风险因素。通过解决当前阿片类药物流行中的一个重大差距,继续进行这一研究和潜在的临床服务开发,有可能通过提高患者安全性。